SLXP

Salix Pharmaceuticals, Ltd. Press Releases

$155.87
*  
7.15
4.81%
Get SLXP Alerts
*Delayed - data as of Sep. 16, 2014  -  Find a broker to begin trading SLXP now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    SLXP After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

UCERIS® (budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA
9/15/2014 5:31:00 PM - Business Wire

Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea
9/2/2014 7:19:00 AM - Business Wire

Salix Announces Early Termination of HSR Waiting Period for Pending Transaction
8/19/2014 7:00:00 AM - Business Wire

Salix Announces Important Topline Results for Microbiome, Culture & Susceptibility, and Key Secondary Efficacy Results for TARGET 3, Rifaximin IBS-D Repeat Treatment Study
8/11/2014 2:01:00 PM - Business Wire

FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain
8/11/2014 7:00:00 AM - Business Wire

Salix Pharmaceuticals Reports 2Q2014 Results
8/7/2014 4:01:00 PM - Business Wire

INVESTOR ALERT – Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd. to Cosmo Pharmaceuticals S.p.A
8/1/2014 2:25:00 PM - Business Wire

Lifshitz & Miller Law Firm Announces Investigation of Design Within Reach, Inc., Family Dollar Stores, Inc., GFI Group Inc., Intermountain Community Bancorp, Rockwood Holdings, Inc., and Salix Pharmaceuticals Ltd.
7/31/2014 1:19:00 PM - PR Newswire

INVESTOR ALERT - Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd. - SLXP
7/28/2014 5:40:00 PM - PR Newswire

Salix Pharmaceuticals Announces 2Q2014 Financial Results Conference Call and Webcast
7/24/2014 7:00:00 AM - Business Wire

INVESTOR ALERT – Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd.
7/21/2014 1:42:00 PM - Business Wire

Salix and Pharming Announce FDA Approval of RUCONEST® for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
7/17/2014 1:00:00 AM - Business Wire

Progenics Holds Conference Call This Morning on FDA Appeal Response Regarding Relistor(R) sNDA for Patients With Chronic Non-Cancer Pain
7/14/2014 7:05:00 AM - GlobeNewswire

FDA Office of Drug Evaluation III Approves Salix’s Request that the FDA Approve the RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain
7/14/2014 7:00:00 AM - Business Wire

SALIX PHARMACEUTICALS, LTD. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger
7/10/2014 11:42:00 AM - PR Newswire

SALIX SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Merger between Salix and Cosmo Pharmaceuticals May be Unfair to Shareholders
7/10/2014 11:30:00 AM - Business Wire

SALIX ALERT: Proposed Sale of Salix Pharmaceuticals, Ltd. Being Investigated by Johnson & Weaver, LLP
7/9/2014 1:32:00 PM - Business Wire

Salix Pharmaceuticals to Combine with Cosmo Technologies to Form Salix Pharmaceuticals, plc
7/8/2014 5:00:00 PM - Business Wire

Salix Announces Statistically Significant Primary Endpoint Result for TARGET 3 Evaluating the Efficacy and Safety of Repeat Treatment with Rifaximin 550mg in Subjects with Irritable Bowel Syndrome with Diarrhea
7/1/2014 7:00:00 AM - Business Wire

Salix Pharmaceuticals to Host Investor Day on July 9, 2014
6/25/2014 7:00:00 AM - Business Wire